ClinicalTrials.gg
CompletedNCT00610727Updated Apr 22, 2026Results posted

Staccato Prochlorperazine Single Dose PK Study

A Phase 1 interventional study of Prochlorperazine 0.5 mg IV over 5 sec and Inhaled prochlorperazine 0.625 mg in Migraine, sponsored by Nova Pneuma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Nova Pneuma Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 697 studies in Migraine Disorders with a site in United States — 92 open to participants now, 114 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
365th of 610
54 · median 78
Started
2004
with 14 others
Phase 1
58 of 697
6 open now
Registered
81st of 697
by date

Among the 697 studies in Migraine Disorders with a site in United States, this one is the 365th largest by enrollment of the 610 interventional ones that give a count, is one of 15 that started in 2004, is one of 58 in phase 1, and was the 81st registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

92 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

87 more — sign in →

All 92 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 697 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of inhaled prochlorperazine

Read the detailed description

The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of a single, inhaled dose of prochlorperazine (PCZ), administered as 1 or 2 puffs in healthy young volunteers.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Migraine, Prochlorperazine aerosol
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects will be male or female subjects between the ages 18 to 45 years, inclusive in good general health as determined by medical history, physical examination, 12-lead , spirometry, blood chemistry profile, hematology, urinalysis and in the opinion of the Principal Investigator.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a known history of allergy or intolerance to phenothiazines or related drugs or who have any disease, by history, physical examination, or laboratory abnormalities that in the investigator's opinion, would present undue risk to the subject, or may confound the interpretation of study results.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Inhaled prochlorperazine 0.625 mg vs IV

    Prochlorperazine 0.5 mg IV over 5 sec crossover Inhaled prochlorperazine 0.625 mg

    Drug: Prochlorperazine 0.5 mg IV over 5 sec · Drug: Inhaled prochlorperazine 0.625 mg · Drug: Prochlorperazine 10 mg IV over 5 sec

  • Experimental
    Inhaled prochlorperazine 1.25 mg

    Inhaled Staccato prochlorperazine 1.25 mg

    Drug: Inhaled prochlorperazine 1.25 mg

  • Experimental
    Inhaled prochlorperazine 2.5 mg

    Inhaled Staccato prochlorperazine 2.5 mg

    Drug: Inhaled prochlorperazine 2.5 mg

  • Experimental
    Inhaled prochlorperazine 5 mg

    Inhaled Staccato prochlorperazine 5 mg

    Drug: Inhaled prochlorperazine 5 mg

  • Experimental
    Inhaled prochlorperazine 10 mg

    Inhaled Staccato prochlorperazine 10 mg

    Drug: Inhaled prochlorperazine 10 mg

  • Placebo comparator
    inhaled Placebo

    inhaled Staccato Placebo (0 mg)

    Drug: Inhaled placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Peak (Tmax)

    Time from dose to peak prochlorperazine concentration

    Time frame: 24 hours

Secondary outcomes

  1. Absolute Bioavailability of Inhaled Prochlorperazine

    Absolute bioavailability of inhaled prochlorperazine via AUC infinity

    Time frame: 24 hours

  2. Dose Proportionality of Inhaled Prochlorperazine by Power Analysis

    Dose proportionality by power analysis examines the linear regression of the log-AUC versus log-Dose on a by-patient basis across all doses administered. The slope and 90% confidence interval (CI) provide a clear, quantitative (best practices) assessment of the relationship of drug delivered to dose administered. The units on such analyses are generally those of slope (rise over run), with 1.000 being "perfect". Although any positive slope might be considered clinically useful, a 90% CI within the criteria of 0.800-1.250 may be considered a delivery system which is "as good as it gets".

    Time frame: 24 hours

07

Results

Posted Nov 5, 2018

Participant flow

Participant flow — Overall Study
MilestoneQualification & Crossover Arm, Inhaled Prochlorperazine vs IVInhaled Prochlorperazine 1.25 mgInhaled Prochlorperazine 2.5 mgInhaled Prochlorperazine 5 mgInhaled Prochlorperazine 10 mgInhaled Placebo
Started1488888
Completed1488888
Not completed000000

Outcome measures

PrimaryTime to Peak (Tmax)

Time from dose to peak prochlorperazine concentration

Time frame:
24 hours
Reported as:
Median · hours
Time to Peak (Tmax)
hours0.5 mg 5 Sec IV0.625 mg Inhaled Prochlorperazine1.25 mg Inhaled2.5 mg Inhaled5 mg Inhaled10 mg Inhaled
Time to Peak (Tmax)0.042 (0.025 to 0.067)0.033 (0.025 to 0.042)0.025 (0.013 to 0.082)0.033 (0.017 to 0.033)0.040 (0.017 to 0.115)0.033 (0.013 to 0.108)
SecondaryAbsolute Bioavailability of Inhaled Prochlorperazine

Absolute bioavailability of inhaled prochlorperazine via AUC infinity

Time frame:
24 hours
Reported as:
Geometric least squares mean · Fraction absorbed
Absolute Bioavailability of Inhaled Prochlorperazine
Fraction absorbedBioavailability Crossover Arm
Absolute Bioavailability of Inhaled Prochlorperazine0.98 (0.73 to 1.34)
SecondaryDose Proportionality of Inhaled Prochlorperazine by Power Analysis

Dose proportionality by power analysis examines the linear regression of the log-AUC versus log-Dose on a by-patient basis across all doses administered. The slope and 90% confidence interval (CI) provide a clear, quantitative (best practices) assessment of the relationship of drug delivered to dose administered. The units on such analyses are generally those of slope (rise over run), with 1.000 being "perfect". Although any positive slope might be considered clinically useful, a 90% CI within the criteria of 0.800-1.250 may be considered a delivery system which is "as good as it gets".

Time frame:
24 hours
Reported as:
Geometric least squares mean · Slope of Power Regression
Dose Proportionality of Inhaled Prochlorperazine by Power Analysis
Slope of Power RegressionAll Subjects Receiving Inhaled Prochloperazine
Dose Proportionality of Inhaled Prochlorperazine by Power Analysis1.089 (.99 to 1.2)

Adverse events

Collected over Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Prochlorperazine 10 mg0/14 (0%)0/14 (0%)6/14 (42.9%)
IV Prochlorperazine 0.5 mg0/8 (0%)0/8 (0%)0/8 (0%)
Inhaled Prochlorperazine 0.6250/8 (0%)0/8 (0%)0/8 (0%)
Inhaled Prochlorperazine 1.25 mg0/8 (0%)0/8 (0%)5/8 (62.5%)
Inhaled Prochlorperazine 2.5 mg0/8 (0%)0/8 (0%)3/8 (37.5%)
Inhaled Prochlorperazine 5 mg0/8 (0%)0/8 (0%)0/8 (0%)
Inhaled Prochlorperazine 10 mg0/8 (0%)0/8 (0%)4/8 (50%)
Inhaled Placebo0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventIV Prochlorperazine 10 mgIV Prochlorperazine 0.5 mgInhaled Prochlorperazine 0.625Inhaled Prochlorperazine 1.25 mgInhaled Prochlorperazine 2.5 mgInhaled Prochlorperazine 5 mgInhaled Prochlorperazine 10 mgInhaled Placebo
DizzinessNervous system disorders0/140/80/80/80/80/82/80/8
Throat irritationRespiratory, thoracic and mediastinal disorders0/140/80/82/81/80/81/80/8
SomnolenceNervous system disorders3/140/80/80/80/80/80/80/8
Vision blurredEye disorders0/140/80/81/80/80/80/80/8
Chest painGeneral disorders0/140/80/81/81/80/80/80/8
Sensation of pressure in faceGeneral disorders0/140/80/81/80/80/80/80/8
DysgeusiaNervous system disorders0/140/80/80/81/80/80/80/8
HeadacheNervous system disorders0/140/80/81/80/80/80/80/8
AnxietyPsychiatric disorders1/140/80/80/80/80/81/80/8
NauseaGastrointestinal disorders1/140/80/80/80/80/80/80/8

Baseline characteristics

Safety Population

Age, Categorical
Age, Categorical(Participants)Qualification & Crossover, Inhaled Prochlorperazine vs IVInhaled Prochlorperazine 1.25 mgInhaled Prochlorperazine 2.5 mgInhaled Prochlorperazine 5 mgInhaled Prochlorperazine 10 mgInhaled PlaceboTotal
<=18 years0000000
Between 18 and 65 years148888854
>=65 years0000000
Age, Continuous
Age, Continuous(years)Qualification & Crossover, Inhaled Prochlorperazine vs IVInhaled Prochlorperazine 1.25 mgInhaled Prochlorperazine 2.5 mgInhaled Prochlorperazine 5 mgInhaled Prochlorperazine 10 mgInhaled PlaceboTotal
Mean29.4 ± 7.8625.1 ± 3.4425 ± 4.5726.4 ± 8.9428.8 ± 10.223.5 ± 7.0325.8 ± 7.09
Sex: Female, Male
Sex: Female, Male(Participants)Qualification & Crossover, Inhaled Prochlorperazine vs IVInhaled Prochlorperazine 1.25 mgInhaled Prochlorperazine 2.5 mgInhaled Prochlorperazine 5 mgInhaled Prochlorperazine 10 mgInhaled PlaceboTotal
Female64444426
Male84444428
Region of Enrollment
Region of Enrollment(participants)Qualification & Crossover, Inhaled Prochlorperazine vs IVInhaled Prochlorperazine 1.25 mgInhaled Prochlorperazine 2.5 mgInhaled Prochlorperazine 5 mgInhaled Prochlorperazine 10 mgInhaled PlaceboTotal
United States148888854
08

Study locations

1 site
  • PPD Phase I Clinic
    Austin, Texas 78704-7016, United States
09

References and documents

Publications

  • Avram MJ, Spyker DA, Henthorn TK, Cassella JV. The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clin Pharmacol Ther. 2009 Jan;85(1):71-7. doi: 10.1038/clpt.2008.184. Epub 2008 Oct 1. PubMed 18830225 ↗

Individual participant data

Plan to share: No — IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2004, a primary completion of Oct 2004 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2018, 14 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2008
First posted
Feb 8, 2008
Start
Aug 2004
Primary completionActual
Oct 2004
CompletionActual
Oct 2004
Results first posted
Nov 5, 2018
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00610727
Lead sponsor
Nova Pneuma Inc.
Collaborators
PPD Development, LP
Responsible party
Sponsor
First posted
Feb 8, 2008
Start date
Aug 2004
Primary completion
Oct 2004
Completion
Oct 2004
Results posted
Nov 5, 2018
Last update
Apr 22, 2026

Study contacts

Daniel A Spyker, MD
study director · Alexza Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prochlorperazine

Start the discussion